These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 26600218)

  • 1. Impact of Hepatitis C Virus Infection on Hepatocellular Carcinoma.
    Tholey DM; Ahn J
    Gastroenterol Clin North Am; 2015 Dec; 44(4):761-73. PubMed ID: 26600218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
    Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
    Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
    World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
    Tong MJ; Theodoro CF; Salvo RT
    J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
    Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
    World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance.
    Akuta N; Suzuki F; Sezaki H; Kobayashi M; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30381417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
    Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
    J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study.
    Rinaldi L; Perrella A; Guarino M; De Luca M; Piai G; Coppola N; Pafundi PC; Ciardiello F; Fasano M; Martinelli E; Valente G; Nevola R; Monari C; Miglioresi L; Guerrera B; Berretta M; Sasso FC; Morisco F; Izzi A; Adinolfi LE
    J Transl Med; 2019 Aug; 17(1):292. PubMed ID: 31462268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.
    Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Akita T; Tanaka J; Johnson PJ
    Liver Int; 2019 Mar; 39(3):448-454. PubMed ID: 30312003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
    Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
    Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
    Piñero F; Mendizabal M; Ridruejo E; Herz Wolff F; Ameigeiras B; Anders M; Schinoni MI; Reggiardo V; Palazzo A; Videla M; Alonso C; Santos L; Varón A; Figueroa S; Vistarini C; Adrover R; Fernández N; Perez D; Tanno F; Hernández N; Sixto M; Borzi S; Bruno A; Cocozzella D; Soza A; Descalzi V; Estepo C; Zerega A; de Araujo A; Cheinquer H; Silva M;
    Liver Int; 2019 Jun; 39(6):1033-1043. PubMed ID: 30636361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection.
    Hayes CN; Zhang P; Zhang Y; Chayama K
    Viruses; 2018 Sep; 10(10):. PubMed ID: 30274202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C and hepatocellular carcinoma.
    Fassio E
    Ann Hepatol; 2010; 9 Suppl():119-22. PubMed ID: 20714008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance.
    Huang CF; Yeh ML; Huang CI; Lin YJ; Tsai PC; Lin ZY; Chan SY; Chen SC; Yang HI; Huang JF; Lu SN; Dai CY; Jen CL; Yuan Y; L'Italien G; Wang LY; Lee MH; Yu ML; Chuang WL; Chen CJ
    Oncotarget; 2017 Jul; 8(27):43925-43933. PubMed ID: 28159934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
    Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.
    Aleman S; Rahbin N; Weiland O; Davidsdottir L; Hedenstierna M; Rose N; Verbaan H; Stål P; Carlsson T; Norrgren H; Ekbom A; Granath F; Hultcrantz R
    Clin Infect Dis; 2013 Jul; 57(2):230-6. PubMed ID: 23616492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
    Tabu K; Mawatari S; Oda K; Kumagai K; Inada Y; Uto H; Saisyoji A; Hiramine Y; Hashiguchi M; Tamai T; Hori T; Fujisaki K; Imanaka D; Kure T; Taniyama O; Toyodome A; Ijuin S; Sakae H; Sakurai K; Moriuchi A; Kanmura S; Ido A
    PLoS One; 2020; 15(8):e0237475. PubMed ID: 32790728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.